Zacks: Analysts Expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) Will Announce Earnings of -$0.47 Per Share

Analysts expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.47) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.38). Syros Pharmaceuticals reported earnings per share of ($0.54) in the same quarter last year, which suggests a positive year-over-year growth rate of 13%. The company is scheduled to report its next earnings report on Thursday, March 5th.

On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.88) per share for the current financial year, with EPS estimates ranging from ($2.01) to ($1.77). For the next financial year, analysts anticipate that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.38) to ($1.56). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million.

Several equities analysts have weighed in on SYRS shares. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. BidaskClub downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 15th. JMP Securities lowered their price target on shares of Syros Pharmaceuticals from $18.00 to $16.00 and set a “market outperform” rating on the stock in a report on Friday, October 18th. Finally, Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $12.89.

Several hedge funds have recently added to or reduced their stakes in SYRS. Tower Research Capital LLC TRC increased its position in Syros Pharmaceuticals by 863.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after purchasing an additional 2,409 shares during the last quarter. Bank of Montreal Can increased its position in Syros Pharmaceuticals by 44.6% in the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $30,000 after purchasing an additional 1,357 shares during the last quarter. Citigroup Inc. increased its position in Syros Pharmaceuticals by 175.0% in the fourth quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock worth $71,000 after purchasing an additional 6,514 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Syros Pharmaceuticals in the fourth quarter worth $77,000. Finally, Trexquant Investment LP bought a new stake in Syros Pharmaceuticals in the fourth quarter worth $92,000.

NASDAQ:SYRS traded up $0.33 during trading hours on Friday, hitting $7.87. 111,000 shares of the stock traded hands, compared to its average volume of 249,803. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.20. Syros Pharmaceuticals has a 1 year low of $4.45 and a 1 year high of $11.93. The company has a market cap of $320.43 million, a price-to-earnings ratio of -3.99 and a beta of 1.58. The stock has a 50 day moving average price of $7.53 and a 200 day moving average price of $7.68.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Recommended Story: P/E Growth (PEG)

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.